"I am pleased to join Ceregene at this particular juncture in the company's history, as the company has accomplished a lot in its clinical programs for Parkinson's and Alzheimer's disease, and I look forward to help steer these promising therapies through later stage clinical development," said Dr. Siffert. "I have reviewed Ceregene's nonclinical and clinical data to date, and I am particularly excited by the potential that CERE-120 and CERE-110 show to not only reduce the symptoms of Parkinson's disease and Alzheimer's disease, respectively, but also to treat the underlying disease process."
"Joao's breadth of experience in developing novel neurological products will be invaluable to Ceregene as our programs continue to mature," stated Dr. Bartus. "I personally look forward to working with Joao to refine and execute our clinical and regulatory strategies and am pleased to welcome someone with such experience and success to help lead our clinical programs as a key member of our executive team."
Ceregene, Inc. is a San Diego-based biotechnology company focused on
the delivery of nervous system growth factors for the treatment of
neurodegenerative disorders using gene delivery. Ceregene's clinical
programs include CERE-110, an AAV2 based vector expressing nerve growth
factor that is currently in Phase 1/2 studies for the treatment of
Alzheimer's disease, and CERE-120 (AAV2-Neurturin) currently in a
controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are
in preclinical development for ALS (Lou Gehrig's disease) and ocular
disorders, respectively. Ceregene was launched in January 2001, and the
company's investors include Alta Partners, MPM Capital, Investor Growth
Capital and Cell Genesys (Nasdaq:
Copyright©2007 PR Newswire.
All rights reserved